ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

30 Apr 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

03 Apr 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

21 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

07 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

06 Mar 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

26 Feb 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

22 Feb 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

20 Feb 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

05 Feb 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

09 Nov 2023 11:02:36 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

06 Oct 2023 09:03:00 By Nasdaq GlobeNewswire

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

03 Oct 2023 09:03:40 By Nasdaq GlobeNewswire

FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study

19 Sep 2023 22:49:48 By Nasdaq GlobeNewswire

ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

10 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

20 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

15 May 2023 09:00:00 By Nasdaq GlobeNewswire

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

11 May 2023 19:01:24 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

09 May 2023 09:10:46 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

28 Mar 2023 09:39:51 By Nasdaq GlobeNewswire